Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
7,011,892
-
Total 13F shares
-
2,108,117
-
Share change
-
-714,114
-
Total reported value
-
$4,279,068
-
Price per share
-
$2.03
-
Number of holders
-
20
-
Value change
-
-$1,739,763
-
Number of buys
-
7
-
Number of sells
-
4
Institutional Holders of Edesa Biotech, Inc. - Common Shares, without par value (EDSA) as of Q2 2025
As of 30 Jun 2025,
Edesa Biotech, Inc. - Common Shares, without par value (EDSA) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,108,117 shares.
The largest 10 holders included
Velan Capital Investment Management LP, Rubric Capital Management LP, Nantahala Capital Management, LLC, COMMONWEALTH EQUITY SERVICES, LLC, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, VANGUARD GROUP INC, Tower Research Capital LLC (TRC), Royal Bank of Canada, and UBS Group AG.
This page lists
20
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.